In contrast, progressive CLL emerged later, primarily after two or more years of treatment, with BTK and/or PLCG2 mutations detected in 80% of these cases, consistent with their known association with ibrutinib resistance. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.